Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus Gemcitabine and S1 in Advanced Biliary Tract Carcinoma
NCT05822453Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2023
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in biliary tract carcinoma (BTC), sponsored by Peking Union Medical College Hospital. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT05822453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05822453.